Christopher A Thomas, MD
Critical Care (Intensivists) · Falls Church
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Inova Health Care Services · 1,821 clinicians in this group
Hospitals listed: Inova Fairfax Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Thomas’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Virginia 0101271995Physician · since 2021 · expires 2028-09-30Told the state board they are board certified.Current ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
2 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Internal Medicine: Critical Care Medicinecertified 2021 · through 2031
- Internal Medicine: Pulmonary Diseasecertified 2020 · through 2030
- Internal Medicinecertified 2018 · through 2028
Education
- Georgetown University School Of Medicine - Washington DC2015
Residency and fellowship
- Stanford University School of Medicine, Pulmonary & Critical Care MedicineStanford, CA · 2021
- Brown University School of Medicine, Internal MedicineProvidence, RI · 2018
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Inova Fairfax HospitalFalls Church, VAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Inova Health System, which runs 5 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.1 to 14.7) · 1,314 cases, Jan 2024 – Dec 2024Better than the national rate — Pressure ulcer rate: 0.08 (0 to 0.42) · 18,592 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.556, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.574, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.491, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.499, Oct 2024 – Sep 2025
See every measure and the patient survey for Inova Fairfax Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.1 to 14.7) · 1,314 cases | Worse | Jan 2024 – Dec 2024 |
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.42) · 18,592 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.556 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.574 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.491 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.499 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.17 (0.5 to 1.84) · 4,823 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.7 to 1.02) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 149.1 (122.38 to 175.82) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 367 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 205 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 370 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 1,423 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 1,212 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.9 · 847 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 8,297 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.28) · 21,070 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.09 to 0.39) · 22,620 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.55 (2.34 to 4.75) · 7,218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.87 to 2.69) · 3,681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.45 (1.53 to 3.37) · 6,582 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.72 (5.02 to 10.42) · 3,557 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.14 (5.1 to 9.18) · 3,672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.43 to 2.97) · 1,556 cases | No different | Jul 2022 – Jun 2024 |
| SSI - Abdominal HysterectomyInfections | 0.969 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.672 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.5 · 546 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 1,625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -12.5 · 521 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.3 · 1,633 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.6 · 1,273 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 1,266 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.8 to 5.9) · 1,314 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.2 · 270 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.7 · 255 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.6 to 15) · 1,020 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 1,648 cases | No different | Jan 2024 – Dec 2024 |
What patients said (877 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$59,909
Medicare paid this office $59,909 for 221 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $21,702 | $100 |
| Critical care, first 30-74 minutes | 45 | $19,538 | $179 |
| Long return visit (40+ min) | 48 | $7,788 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,985 | $142 |
| New patient visit (60+ min) | 17 | $2,653 | $156 |
See all 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $21,702 | $100 |
| Critical care, first 30-74 minutes | 45 | $19,538 | $179 |
| Long return visit (40+ min) | 48 | $7,788 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,985 | $142 |
| New patient visit (60+ min) | 17 | $2,653 | $156 |
| Test for exercise-induced lung stress | 42 | $737 | $18 |
| Test to measure expiratory airflow and volume | 38 | $262 | $7 |
Who their Medicare patients are
221 Original Medicare patients in 2024. Average age 71 · Women 50% · Also on Medicaid 13% · Health risk score 2.39. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · Coronary heart disease 57% · Heart failure 56% · COPD 52% · Chronic kidney disease 48% · Diabetes 42% · Atrial fibrillation 36% · Depression 30% · Cancer 13% · Stroke 11% · Dementia 8%.
The office billed $226,734, Medicare allowed $76,070 and paid $59,909; for 565 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 221 | 565 | 71 | 2.39 | $226,734 | $59,909 |
| 2023 | 215 | 527 | 71 | 2.55 | $240,294 | $66,264 |
| 2022 | 188 | 456 | 72 | 2.65 | $192,673 | $55,305 |
| 2021 | 25 | 37 | 73 | 2.22 | $20,263 | $4,986 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Critical care, first 30-74 minutes | 73 | $29,565 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $20,853 | $104 |
| Long return visit (40+ min) | 26 | $4,815 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,065 | $153 |
| Test for exercise-induced lung stress | 41 | $751 | $18 |
2022: 4 services
| Critical care, first 30-74 minutes | 58 | $25,902 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $15,727 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,711 | $177 |
| Test for exercise-induced lung stress | 39 | $752 | $19 |
2021: 1 service
| Critical care, first 30-74 minutes | 15 | $3,373 | $198 |
Drugs they prescribed that Part D paid
$1,262,620
Pharmacies billed $1,262,620 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
289 generic and 109 brand-name prescriptions · $1,262,620 in drug cost · 16 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Uptravi | 12 | $268,178 | $22,348 |
| Ofev | 17 | $215,823 | $12,695 |
| Opsumit | 15 | $189,519 | $12,635 |
| Adempas | 13 | $183,232 | $14,095 |
| Orenitram Er | 18 | $182,838 | $10,158 |
See all 14 drugs
| Uptravi | 12 | $268,178 | $22,348 |
| Ofev | 17 | $215,823 | $12,695 |
| Opsumit | 15 | $189,519 | $12,635 |
| Adempas | 13 | $183,232 | $14,095 |
| Orenitram Er | 18 | $182,838 | $10,158 |
| Tadalafil | 27 | $24,621 | $912 |
| Sildenafil Citrate | 13 | $6,323 | $486 |
| Tacrolimus | 12 | $1,641 | $137 |
| Mycophenolate Mofetil | 18 | $1,049 | $58 |
| Spironolactone | 15 | $266 | $18 |
| Prednisone | 31 | $214 | $7 |
| Gabapentin | 13 | $195 | $15 |
| Pantoprazole | 15 | $115 | $8 |
| Furosemide | 22 | $96 | $4 |
Year by year
| 2024 | 398 | 64 | None | 27% | $1,262,620 |
| 2023 | 213 | 27 | None | None | $1,104,492 |
| 2022 | 112 | 17 | None | 45% | $452,059 |
| 2021 | 50 | 11 | 0% (0) | 76% | $14,286 |
| 2020 | 88 | 19 | 0% (0) | 80% | $96,774 |
| 2019 | 51 | 12 | 0% (0) | 69% | $12,121 |
| 2018 | 392 | 49 | None | None | $24,398 |
| 2017 | 756 | 79 | None | None | $35,227 |
| 2016 | 570 | 96 | None | None | $60,454 |
| 2015 | 83 | 25 | None | 23% | $12,810 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Uptravi | 26 | $583,091 | $22,427 |
| Opsumit | 23 | $295,666 | $12,855 |
| Adempas | 11 | $162,261 | $14,751 |
| Tadalafil | 18 | $24,304 | $1,350 |
| Prednisone | 29 | $252 | $9 |
| Potassium Chloride | 11 | $108 | $10 |
2022: 1 drug
| Opsumit | 15 | $170,519 | $11,368 |
2020: 3 drugs
| Combivent Respimat | 13 | $7,506 | $577 |
| Advair Hfa | 12 | $4,841 | $403 |
| Advair Diskus | 12 | $3,920 | $327 |
2019: 1 drug
| Symbicort | 14 | $4,667 | $333 |
2018: 10 drugs
| Advair Diskus | 11 | $7,750 | $705 |
| Ventolin Hfa | 13 | $819 | $63 |
| Gabapentin | 23 | $201 | $9 |
| Omeprazole | 23 | $164 | $7 |
| Furosemide | 21 | $125 | $6 |
| Atorvastatin | 24 | $120 | $5 |
| Amlodipine Besylate | 31 | $94 | $3 |
| Lisinopril | 18 | $64 | $4 |
| Carvedilol | 15 | $54 | $4 |
| Sertraline | 11 | $38 | $3 |
2017: 20 drugs
| Advair Diskus | 14 | $5,760 | $411 |
| Atorvastatin | 46 | $581 | $13 |
| Amlodipine Besylate | 41 | $433 | $11 |
| Levothyroxine | 18 | $424 | $24 |
| Enalapril Maleate | 13 | $354 | $27 |
| Omeprazole | 39 | $342 | $9 |
| Gabapentin | 27 | $312 | $12 |
| Sucralfate | 13 | $212 | $16 |
| Carvedilol | 37 | $189 | $5 |
| Trazodone | 14 | $181 | $13 |
| Furosemide | 38 | $161 | $4 |
| Lisinopril | 42 | $160 | $4 |
| Sertraline | 17 | $135 | $8 |
| Metformin | 27 | $131 | $5 |
| Amitriptyline | 13 | $126 | $10 |
| Metoprolol | 23 | $99 | $4 |
| Pantoprazole | 19 | $91 | $5 |
| Hydrochlorothiazide | 18 | $57 | $3 |
| Ibuprofen | 11 | $54 | $5 |
| Losartan-Hydrochlorothiazide | 11 | $40 | $4 |
2016: 13 drugs
| Advair Diskus | 19 | $9,698 | $510 |
| Atorvastatin | 41 | $710 | $17 |
| Levetiracetam | 11 | $464 | $42 |
| Metoprolol | 15 | $436 | $29 |
| Omeprazole | 34 | $294 | $9 |
| Levothyroxine | 13 | $259 | $20 |
| Amlodipine Besylate | 32 | $246 | $8 |
| Lisinopril | 34 | $149 | $4 |
| Furosemide | 42 | $105 | $2 |
| Metformin | 15 | $95 | $6 |
| Metoprolol | 16 | $76 | $5 |
| Pantoprazole | 11 | $70 | $6 |
| Topiramate | 12 | $49 | $4 |
Money from drug and device companies
$1,544 in 2025
| 2025 | 14 | 56 | None | $1,544 |
| 2024 | 12 | 55 | None | $1,926 |
| 2023 | 7 | 32 | $2,100 | $3,819 |
| 2022 | 4 | 13 | None | $462 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| United Therapeutics | Tyvaso | $524 | 16 payments
|
| Actelion Pharmaceuticals US | Opsumit | $261 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $174 | 9 payments
|
| Merck Sharp & Dohme | Winrevair | $135 | 2 payments
|
| Insmed | Arikayce | $121 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $85 | 3 payments
|
See all 52 published payments
| United Therapeutics | Meals · 2025-12-17 | Tyvaso | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-15 | Adempas | $28 |
| Abbvie | Meals · 2025-12-01 | Emblaveo | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-21 | Jascayd | $19 |
| United Therapeutics | Meals · 2025-11-20 | Remodulin | $24 |
| Insmed | Meals · 2025-11-19 | Arikayce | $19 |
| United Therapeutics | Meals · 2025-11-05 | Orenitram | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-04 | Livtencity | $30 |
| Actelion Pharmaceuticals US | Meals · 2025-10-20 | Uptravi | $35 |
| Actelion Pharmaceuticals US | Meals · 2025-10-18 | Opsumit | $139 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-14 | Jascayd | $31 |
| Actelion Pharmaceuticals US | Meals · 2025-10-13 | Uptravi | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-10 | Jascayd | $22 |
| United Therapeutics | Meals · 2025-09-25 | Tyvaso | $20 |
| United Therapeutics | Meals · 2025-09-24 | Remodulin | $26 |
| United Therapeutics | Meals · 2025-08-21 | Orenitram | $33 |
| Insmed | Meals · 2025-08-14 | Arikayce | $21 |
| Abbvie | Meals · 2025-08-06 | Avycaz | $26 |
| Actelion Pharmaceuticals US | Meals · 2025-08-05 | Uptravi | $30 |
| United Therapeutics | Meals · 2025-07-23 | Remodulin | $28 |
| Insmed | Meals · 2025-07-15 | Arikayce | $20 |
| United Therapeutics | Meals · 2025-07-02 | Orenitram | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-26 | Ofev | $16 |
| Insmed | Meals · 2025-06-19 | Arikayce | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-05 | Ofev | $15 |
| Insmed | Meals · 2025-06-04 | Arikayce | $21 |
| Invivyd | Meals · 2025-06-03 | Pemgarda | $17 |
| Baxter Healthcare | Meals · 2025-05-28 | Hillrom - Monarch Airway Clearance System | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-15 | Ofev | $14 |
| Merck Sharp & Dohme | Meals · 2025-05-12 | Winrevair | $17 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-09 | Ofev | $24 |
| United Therapeutics | Meals · 2025-05-01 | Orenitram | $25 |
| Johnson & Johnson Health Care Systems | Meals · 2025-04-29 | Uptravi | $21 |
| United Therapeutics | Meals · 2025-04-28 | Tyvaso | $117 |
| United Therapeutics | Meals · 2025-04-28 | Tyvaso | $56 |
| Merck Sharp & Dohme | Meals · 2025-04-26 | None | $118 |
| United Therapeutics | Meals · 2025-04-23 | Tyvaso | $22 |
| Invivyd | Meals · 2025-04-07 | Pemgarda | $15 |
| Actelion Pharmaceuticals US | Meals · 2025-03-17 | Uptravi | $25 |
| La Jolla Pharmaceutical | Meals · 2025-02-27 | Giapreza | $18 |
| United Therapeutics | Meals · 2025-02-26 | Tyvaso | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-20 | Ofev | $14 |
| Insmed | Meals · 2025-02-19 | Arikayce | $20 |
| United Therapeutics | Meals · 2025-02-06 | Tyvaso | $16 |
| United Therapeutics | Meals · 2025-02-05 | Orenitram | $33 |
| Eurofins Viracor | Meals · 2025-01-31 | None | $16 |
| United Therapeutics | Meals · 2025-01-22 | Tyvaso | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-21 | Livtencity | $23 |
| ANI Pharmaceuticals | Meals · 2025-01-16 | Purified Cortrophin Gel | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-10 | Ofev | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-08 | Livtencity | $32 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-08 | Adempas | $29 |
See earlier years (2024, 2023, 2022)
2024: $1,926
| ANI Pharmaceuticals | Purified Cortrophin Gel | $508 | 4 payments
|
| United Therapeutics | Orenitram | $502 | 13 payments
|
| Actelion Pharmaceuticals US | Opsumit | $190 | 6 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $134 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $118 | 7 payments
|
| Vifor Pharma | Zemaira | $113 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $67 | 2 payments
|
| Merck Sharp & Dohme | Winrevair | $63 | 3 payments
|
| Mylan Specialty L.P. | Tobi Podhaler | $61 | 2 payments
|
| Paratek Pharmaceuticals | Nuzyra | $58 | 3 payments
|
| Abbvie | Teflaro | $56 | 2 payments
|
| Melinta Therapeutics | Rezzayo | $55 | 3 payments
|
2023: $3,819
| Actelion Pharmaceuticals US | Opsumit | $3,224 | 11 payments
|
| United Therapeutics | Orenitram | $295 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $116 | 6 payments
|
| Mylan Specialty L.P. | Tobi Podhaler | $50 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $47 | 2 payments
|
| AbbVie | Avycaz | $44 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $43 | 2 payments
|
2022: $462
| Actelion Pharmaceuticals US | Uptravi | $195 | 2 payments
|
| United Therapeutics | Remodulin | $120 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $74 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $73 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285012864
- Licence
- RI LP03335, VA 0101271995Virginia 0101271995: Current Active
- Trained
- Georgetown University School of Medicine, 2015
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- Po Box 37174, Baltimore, MD, 21297
- NPI first listed
- 2015-05-14
- NPI last updated
- 2022-05-10
- NPI record certified
- 2022-05-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2501 Parkers Ln, Alexandria, VA, 22306 · 3600 Joseph Siewick Dr, Fairfax, VA, 22033 · 8110 Gatehouse Rd Ste 600w, Falls Church, VA, 22042 · 44045 Riverside Pkwy, Leesburg, VA, 20176 · 300 Pasteur Dr Rm H3143, Stanford, CA, 94305